指南与共识乳腺癌

生物标志物指导早期浸润性乳腺癌辅助全身治疗决策:美国临床肿瘤学会临床实践指南聚焦更新

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
指南 / 共识 · J Clin Oncol · 2017-07-10

本聚焦更新评估MammaPrint检测用于指导早期浸润性乳腺癌辅助全身治疗决策。基于III期随机MINDACT研究(6693例早期乳腺癌女性)及其他文献,专家组建议:激素受体阳性、HER2阴性、淋巴结阴性且临床高风险患者可使用MammaPrint以辅助决定是否省略辅助化疗;临床低风险患者无临床效用。激素受体阳性、HER2阴性、1至3枚淋巴结阳性且临床高风险患者可使用以辅助决定是否省略化疗,但应告知不能排除化疗获益,尤其是超过1枚淋巴结受累者;临床低风险淋巴结阳性患者及HER2阳性或三阴性乳腺癌患者不应使用。

要点

  • 激素受体阳性、HER2阴性、淋巴结阴性且临床高风险早期乳腺癌可使用MammaPrint辅助决定是否省略辅助化疗。
  • 临床低风险患者不论MammaPrint基因组风险组均未从化疗获益,MammaPrint无临床效用。
  • 激素受体阳性、HER2阴性、1至3枚淋巴结阳性且临床高风险可使用MammaPrint,但应告知不能排除化疗获益。

核心结论

  • 激素受体阳性、HER2阴性、淋巴结阴性且临床高风险早期乳腺癌可使用MammaPrint辅助决定是否省略辅助化疗。
  • 临床低风险患者不论基因组MammaPrint风险组均未从化疗获益,MammaPrint在该类患者无临床效用。
  • 激素受体阳性、HER2阴性、1至3枚淋巴结阳性且临床高风险可使用MammaPrint辅助决定是否省略辅助化疗,但应告知不能排除化疗获益,尤其是超过1枚淋巴结受累者。
  • 临床低风险淋巴结阳性患者及HER2阳性或三阴性乳腺癌患者不应使用MammaPrint指导辅助全身治疗决策,因缺乏确定性数据。

研究设计与样本

  • 美国临床肿瘤学会(ASCO)采用信号法进行指南聚焦更新。
  • 触发信号为III期随机MINDACT研究(Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy)的发表,该研究在6693例早期乳腺癌女性中评估MammaPrint检测。
  • 专家组审查MINDACT研究结果及其他已发表MammaPrint文献以评估临床效用证据。

主要发现

  • MINDACT研究在6693例早期乳腺癌女性中评估MammaPrint检测。
  • 临床低风险女性不论基因组MammaPrint风险组均未从化疗获益。

关键数值与推荐

  • 激素受体阳性、HER2阴性、淋巴结阴性且临床高风险患者:可使用MammaPrint辅助决定是否省略辅助全身化疗。
  • 临床低风险患者:MammaPrint无临床效用。
  • 激素受体阳性、HER2阴性、1至3枚淋巴结阳性且临床高风险患者:可使用MammaPrint辅助决定是否省略辅助全身化疗,但应告知不能排除化疗获益,尤其是超过1枚淋巴结受累者。
  • 激素受体阳性、HER2阴性、淋巴结阳性且临床低风险患者:不应使用MammaPrint指导辅助全身治疗决策。
  • HER2阳性或三阴性乳腺癌患者:不应使用MammaPrint指导辅助全身治疗决策。

临床怎么用

  • 激素受体阳性、HER2阴性、淋巴结阴性且临床高风险早期乳腺癌可使用MammaPrint辅助决定是否省略辅助化疗。
  • 临床低风险患者不论MammaPrint基因组风险组均未从化疗获益,MammaPrint无临床效用。
  • 激素受体阳性、HER2阴性、1至3枚淋巴结阳性且临床高风险可使用MammaPrint辅助决定是否省略辅助化疗,但应告知不能排除化疗获益,尤其是超过1枚淋巴结受累者。
  • 临床低风险淋巴结阳性患者及HER2阳性或三阴性乳腺癌患者不应使用MammaPrint指导辅助全身治疗决策。

局限性

  • 激素受体阳性、HER2阴性、淋巴结阳性且临床低风险患者及HER2阳性或三阴性乳腺癌患者缺乏确定性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on the use of adjuvant systemic therapy. Methods ASCO uses a signals approach to facilitate guideline updates. For this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy) study to evaluate the MammaPrint assay in 6,693 women with early-stage breast cancer provided a signal. An expert panel reviewed the results of the MINDACT study along with other published literature on the MammaPrint assay to assess for evidence of clinical utility. Recommendations If a patient has hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer, the MammaPrint assay may be used in those with high clinical risk to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to identify a good-prognosis population with potentially limited chemotherapy benefit. Women in the low clinical risk category did not benefit from chemotherapy regardless of genomic MammaPrint risk group. Therefore, the MammaPrint assay does not have clinical utility in such patients. If a patient has hormone receptor-positive, HER2-negative, node-positive breast cancer, the MammaPrint assay may be used in patients with one to three positive nodes and a high clinical risk to inform decisions on withholding adjuvant systemic chemotherapy. However, such patients should be informed that a benefit from chemotherapy cannot be excluded, particularly in patients with greater than one involved lymph node. The clinician should not use the MammaPrint assay to guide decisions on adjuvant systemic therapy in patients with hormone receptor-positive, HER2-negative, node-positive breast cancer at low clinical risk, nor any patient with HER2-positive or triple-negative breast cancer, because of the lack of definitive data in these populations. Additional information can be found at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Krop I, Ismaila N, Andre F, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2017. PMID: 28692382. doi:10.1200/JCO.2017.74.0472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。